Molecular typing of Neisseria gonorrhoeae – a study of 2013 isolates
This report describes the second molecular typing survey of N. gonorrhoeae across the EU/EEA and provides recent information on NG-MAST STs/Gs and genotypes based on WGS circulating in 21 EU/EEA Member States.
Understanding drug-resistant gonorrhoea: an ECDC whole genome sequencing study
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens? The first study of this kind within an international surveillance programme for sexually transmitted infections shows distribution of drug-resistant gonorrhoea strains across Europe.
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia
This rapid risk assessment aims to assess the risk of XDR Neisseria gonorrhoeae spreading further in the EU/EEA and provide some options for response.
Communicable disease threats report, 22-28 April 2018, week 17
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 22-28 April 2018 and includes updates on dengue, chikungunya, seasonal influenza, yellow fever, gonorrhoea and cholera.
Communicable disease threats report, 25-31 March 2018, week 13
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 25-31 March 2018 and includes updates on dengue, chikungunya, measles, listeria, Borna diseases and gonorrhoeae.
European Gonococcal Antimicrobial Surveillance Programme external quality assessment scheme for Neisseria gonorrhoeae antimicrobial susceptibility testing, 2017
An EQA scheme for antimicrobial susceptibility testing in Neisseria gonorrhoeae has been available to laboratories participating in ECDC’s European Sexually Transmitted Infections (STI) surveillance network since 2010. This is the third EQA to be published on antimicrobial susceptibility testing in Neisseria gonorrhoeae.
Gonorrhoea strains across Europe becoming more susceptible to main treatment options
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
Gonococcal antimicrobial susceptibility surveillance in Europe, 2015
The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) follows a decentralised and centralised testing model. In 2015, 24 EU/EEA Member States participated in Euro-GASP, 17 through decentralised testing.
Euro-GASP external quality assessment (EQA) scheme for Neisseria gonorrhoeae antimicrobial susceptibility testing 2016
The EQA scheme is available to all laboratories in the STI surveillance network, which are mainly national reference laboratories or provide expert services (national or regional) in respect to N. gonorrhoeae diagnostics and antimicrobial susceptibility testing.